ARRY saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 13, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 42 instances where the indicator turned negative. In 39 of the 42 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on October 07, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARRY as a result. In 79 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for ARRY entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ARRY's RSI Oscillator exited the oversold zone, 29 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +5.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARRY advanced for three days, in 202 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
ARRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. ARRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ARRY's P/B Ratio (15.432) is slightly higher than the industry average of (4.841). P/E Ratio (56.911) is within average values for comparable stocks, (100.974). Projected Growth (PEG Ratio) (0.399) is also within normal values, averaging (1.699). Dividend Yield (0.000) settles around the average of (0.013) among similar stocks. P/S Ratio (0.543) is also within normal values, averaging (5.133).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.
The Aroon Indicator for AVXL entered a downward trend on October 13, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 278 similar instances where the Aroon Indicator formed such a pattern. In 240 of the 278 cases the stock moved lower. This puts the odds of a downward move at 86%.
The 10-day moving average for AVXL crossed bearishly below the 50-day moving average on September 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVXL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where AVXL advanced for three days, in 204 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
AVXL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.937) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. AVXL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AVXL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ARRY | AVXL | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 57 | 54 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 97 Overvalued | 22 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 94 | |
PRICE GROWTH RATING 1..100 | 90 | 94 | |
P/E GROWTH RATING 1..100 | 22 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AVXL's Valuation (22) in the Biotechnology industry is significantly better than the same rating for ARRY (97). This means that AVXL’s stock grew significantly faster than ARRY’s over the last 12 months.
AVXL's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARRY (100). This means that AVXL’s stock grew similarly to ARRY’s over the last 12 months.
AVXL's SMR Rating (94) in the Biotechnology industry is in the same range as ARRY (100). This means that AVXL’s stock grew similarly to ARRY’s over the last 12 months.
ARRY's Price Growth Rating (90) in the Biotechnology industry is in the same range as AVXL (94). This means that ARRY’s stock grew similarly to AVXL’s over the last 12 months.
ARRY's P/E Growth Rating (22) in the Biotechnology industry is significantly better than the same rating for AVXL (100). This means that ARRY’s stock grew significantly faster than AVXL’s over the last 12 months.
| ARRY | AVXL | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 81% | 2 days ago 74% |
| Stochastic ODDS (%) | 2 days ago 74% | 2 days ago 77% |
| Momentum ODDS (%) | 2 days ago 90% | N/A |
| MACD ODDS (%) | 2 days ago 90% | N/A |
| TrendWeek ODDS (%) | 2 days ago 88% | 2 days ago 88% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 85% |
| Advances ODDS (%) | 15 days ago 79% | 27 days ago 79% |
| Declines ODDS (%) | 2 days ago 89% | 8 days ago 85% |
| BollingerBands ODDS (%) | 2 days ago 87% | 2 days ago 81% |
| Aroon ODDS (%) | 2 days ago 83% | 2 days ago 86% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARRY’s FA Score shows that 1 FA rating(s) are green while AVXL’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARRY’s TA Score shows that 4 TA indicator(s) are bullish while AVXL’s TA Score has 4 bullish TA indicator(s).
ARRY (@Alternative Power Generation) experienced а -12.07% price change this week, while AVXL (@Biotechnology) price change was -7.50% for the same time period.
The average weekly price growth across all stocks in the @Alternative Power Generation industry was -6.87%. For the same industry, the average monthly price growth was -3.20%, and the average quarterly price growth was -34.94%.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.49%. For the same industry, the average monthly price growth was -19.00%, and the average quarterly price growth was -19.88%.
ARRY is expected to report earnings on Nov 05, 2026.
AVXL is expected to report earnings on Nov 30, 2026.
The alternative power generation industry consists of companies that operate power facilities converting non-conventional forms of energy into electricity. These energy forms are alternatives to fossil fuels, and many of them are derived from natural resources. Alternative energy forms include solar, wind, hydro, and geothermal steam. A major purpose behind using alternative energy – also called ‘clean’ energy - is to address concerns related to the more conventional fossil fuels, such as the latter’s high carbon dioxide emissions which is often considered a factor in global warming. Alternative power generation has been gaining traction in recent years, and could grow further in the future. Large organizations like Google have invested substantially in wind and solar energy-powered electricity. Some of the prominent U.S. companies operating in the alternative power generation industry includes Ormat Technologies, Inc., TerraForm Power, Inc. and NextEra Energy Partners LP.
@Biotechnology (-8.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TDIV | 115.24 | 1.47 | +1.29% |
| First Trust NASDAQ Technology Dividend Index Fund (TDIV) | |||
| GRF | 9.85 | 0.10 | +1.03% |
| Eagle Capital Growth Fund | |||
| YINN | 25.06 | 0.09 | +0.36% |
| Direxion Daily FTSE China Bull 3X ETF (YINN) | |||
| PAYM | 25.54 | -0.08 | -0.31% |
| TrueShares S&P Autocallable Defensive Income ETF (PAYM) | |||
| SLVX | 13.00 | -0.45 | -3.37% |
| Nicholas Silver Income ETF (SLVX) | |||
A.I.dvisor indicates that over the last year, ARRY has been closely correlated with NXT. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if ARRY jumps, then NXT could also see price increases.
| Ticker / NAME | Correlation To ARRY | 1D Price Change % | ||
|---|---|---|---|---|
| ARRY | 100% | -0.83% | ||
| NXT - ARRY | 66% Closely correlated | +4.61% | ||
| SHLS - ARRY | 60% Loosely correlated | +0.12% | ||
| AXON - ARRY | 53% Loosely correlated | -0.26% | ||
| INO - ARRY | 52% Loosely correlated | -9.67% | ||
| ENPH - ARRY | 50% Loosely correlated | +1.71% | ||
More | ||||